Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
FMR LLC and Abigail P. Johnson report their beneficial ownership of Vaxcyte Inc. common stock in an amended Schedule 13G filing. FMR LLC reports beneficial ownership of 20,798,906.96 shares of common stock, representing 14.4% of the class. FMR LLC has sole voting power over 18,886,452.19 shares and sole dispositive power over 20,798,906.96 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over 20,798,906.96 shares, also amounting to 14.4% of the class, and no voting power. One or more other persons have rights to receive dividends or sale proceeds from these shares, but no such person holds an interest exceeding five percent of Vaxcyte’s outstanding common stock. The securities were acquired through subsidiaries identified in an attached exhibit.
Vaxcyte, Inc. executive Harpreet S. Dhaliwal, Chief Technical Ops Officer, reported an option exercise and related share sale. On August 5, 2026, he exercised stock options covering 17,000 shares of common stock at an exercise price of $24.79 per share from a fully vested option grant, and reported holding 28,000 stock options after the transaction.
The same day, he sold 17,000 common shares at a weighted-average price of $55.004 per share, with trade prices ranging from $55.00 to $55.255, under a Rule 10b5-1 trading plan adopted on April 6, 2026. His reported direct common stock position includes 780 shares acquired through the Employee Stock Purchase Plan on May 15, 2026.
Vaxcyte, Inc. chief operating officer Jim Wassil exercised stock options for 2,250 shares of common stock at $5.35 per share on August 3, 2026, then sold a total of 2,250 shares in two transactions at weighted-average prices of $53.502 and $54.089 per share under a Rule 10b5-1 trading plan. The exercised options were fully vested and exercisable, and 68,898 stock options remained beneficially owned afterward. His reported direct holdings include 781 shares acquired through the company’s employee stock purchase plan on May 15, 2026.
Vaxcyte, Inc. president and CFO Andrew Guggenhime exercised stock options for 10,000 shares of common stock at $5.35 per share on August 3, 2026, then reported sales of 6,956 shares at a weighted-average price of $53.761 and 3,044 shares at $54.178 under a Rule 10b5-1 trading plan adopted March 4, 2026. After these transactions he directly held 216,827 stock options and indirectly held 61,850 common shares through ALG 2025 GRAT HOLDINGS LLC, while his direct common stock position includes 781 shares acquired under the Employee Stock Purchase Plan on May 15, 2026.
Vaxcyte, Inc. is a clinical-stage vaccine company developing pneumococcal conjugate vaccines VAX-31, VAX-24 and VAX-XL, plus programs for Group A Strep (VAX-A1) and Shigella (VAX-GI) using a cell-free protein synthesis platform. Multiple Phase 3 adult and Phase 2 infant trials of VAX-31 are underway or fully enrolled, and a first-in-human Phase 1 study of VAX-A1 began in June 2026.
For the quarter ended June 30, 2026, net loss was $284.3 million (vs. $166.6 million a year earlier), or $1.97 per share, driven primarily by research and development expense of $267.9 million. For the first six months, net loss was $604.9 million on operating expenses of $648.6 million, including $580.6 million in R&D and $68.0 million in general and administrative costs. Operating activities used $513.1 million of cash in the half.
Vaxcyte strengthened its balance sheet with a February 2026 underwritten offering that generated $601.8 million in net proceeds. As of June 30, 2026, cash, cash equivalents and investments totaled about $2.5 billion, which the company states will fund operating and capital needs for at least 12 months. The company is investing heavily in commercial-scale manufacturing, including a long-term Lonza suite in Switzerland and a Thermo Fisher drug-product agreement, and has non-cancelable manufacturing and raw material purchase commitments of $670.2 million.
Vaxcyte, Inc. reported a second-quarter 2026 net loss of $284.3 million, compared to $166.6 million a year earlier, as it increased investment in its pneumococcal conjugate vaccine (PCV) programs. Research and development expenses were $267.9 million and general and administrative expenses were $34.9 million. Cash, cash equivalents and investments were $2,507.7 million as of June 30, 2026.
The company reported full enrollment of its three adult VAX-31 Phase 3 OPUS trials and a Phase 2 infant study, with topline OPUS-1 noninferiority data expected in the fourth quarter of 2026 and OPUS-2 and OPUS-3 results in the first half of 2027. A Phase 1 study of VAX-A1 for Group A Streptococcus is underway, with topline data anticipated in the second half of 2027. Management highlighted approximately $2.5 billion in cash and investments as supporting planned clinical, manufacturing and commercial-readiness milestones.
PCVX insider Andrew Guggenhime filed to sell 10,000 shares of common stock through UBS Financial Services on NASDAQ on 08/03/2026, in connection with an exercise of stock options for cash. The planned sale has an indicated aggregate value of $539,900.00.
Over the prior three months, Guggenhime reported selling 10,000 shares of common stock on 06/18/2026 for $530,000.00 and another 10,000 shares on 07/06/2026 for $572,836.00.
A holder of PCVX common stock, James Wassil, has filed to sell 2,250 shares through UBS Financial Services on the NASDAQ on August 3, 2026, following an exercise of stock options for cash. The filing also lists prior sales over the past three months: 2,250 shares of common stock on June 1, 2026 for $111,416.62, and 2,250 shares on July 1, 2026 for $126,735.98, with the planned sale valued at $121,477.50 based on the stated aggregate market value.
Vaxcyte, Inc. chief executive Grant Pickering exercised stock options for 16,198 shares of common stock at an exercise price of $2.03 per share on July 27, 2026. He then sold 18,198 common shares in market transactions at prices between $54.77 and $56.18 per share under a Rule 10b5-1 trading plan, including sales by trusts for his children. After the derivative transaction, 137,000 option shares remain exercisable.